120 related articles for article (PubMed ID: 28757403)
1. Performance of a palladium-103 line source for prostate brachytherapy implants: A Phase I trial.
Stock R; Beyer D; Kaminetsky J; Ge W
Brachytherapy; 2017; 16(5):1007-1012. PubMed ID: 28757403
[TBL] [Abstract][Full Text] [Related]
2. MRI-assisted radiosurgery: A quality assurance nomogram for palladium-103 and iodine-125 prostate brachytherapy.
Hanania AN; Kudchadker RJ; Bruno TL; Tang C; Anscher MS; Frank SJ
Brachytherapy; 2020; 19(1):38-42. PubMed ID: 31812590
[TBL] [Abstract][Full Text] [Related]
3. 103Pd strings: Monte Carlo assessment of a new approach to brachytherapy source design.
Rivard MJ; Reed JL; DeWerd LA
Med Phys; 2014 Jan; 41(1):011716. PubMed ID: 24387508
[TBL] [Abstract][Full Text] [Related]
4. Dosimetric and volumetric criteria for selecting a source activity and a source type ((125)I or (103)Pd) in the presence of irregular seed placement in permanent prostate implants.
Wuu CS; Ennis RD; Schiff PB; Lee EK; Zaider M
Int J Radiat Oncol Biol Phys; 2000 Jun; 47(3):815-20. PubMed ID: 10837969
[TBL] [Abstract][Full Text] [Related]
5. Brachytherapy in patients with small prostate glands.
Loblaw DA; Wallner K; Dibiase S; Russell K; Blasko J; Ellis W
Tech Urol; 2000 Jun; 6(2):64-9. PubMed ID: 10798802
[TBL] [Abstract][Full Text] [Related]
6. Influence of source batch S dispersion on dosimetry for prostate cancer treatment with permanent implants.
Nuñez-Cumplido E; Perez-Calatayud J; Casares-Magaz O; Hernandez-Armas J
Med Phys; 2015 Aug; 42(8):4933-40. PubMed ID: 26233219
[TBL] [Abstract][Full Text] [Related]
7. Morbidity effect of the time gap between supplemental beam radiation and Pd-103 prostate brachytherapy.
Corriveau J; Wallner K; Merrick G; True L; Cavanagh W; Sutlief S; Butler W
Brachytherapy; 2003; 2(2):108-13. PubMed ID: 15062149
[TBL] [Abstract][Full Text] [Related]
8. Is supplemental external beam radiation therapy necessary for patients with higher risk prostate cancer treated with 103Pd? Results of two prospective randomized trials.
Merrick GS; Wallner KE; Galbreath RW; Butler WM; Fiano R; Orio PF; Adamovich E
Brachytherapy; 2015; 14(5):677-85. PubMed ID: 26051802
[TBL] [Abstract][Full Text] [Related]
9. Dosimetric effects of needle divergence in prostate seed implant using 125I and 103Pd radioactive seeds.
Nath S; Chen Z; Yue N; Trumpore S; Peschel R
Med Phys; 2000 May; 27(5):1058-66. PubMed ID: 10841410
[TBL] [Abstract][Full Text] [Related]
10. 20 Gy versus 44 Gy supplemental beam radiation with Pd-103 prostate brachytherapy: preliminary biochemical outcomes from a prospective randomized multi-center trial.
Wallner K; Merrick G; True L; Sherertz T; Sutlief S; Cavanagh W; Butler W
Radiother Oncol; 2005 Jun; 75(3):307-10. PubMed ID: 16086912
[TBL] [Abstract][Full Text] [Related]
11. Impact of urinary catheterization on dosimetry after prostate implant brachytherapy with palladium-103 or iodine-125.
Shirvani SM; Kudchadker RJ; Bruno TL; Likhacheva A; Swanson DA; Frank SJ
Brachytherapy; 2011; 10(4):269-74. PubMed ID: 21296031
[TBL] [Abstract][Full Text] [Related]
12. Twelve-month prostate-specific antigen values and perineural invasion as strong independent prognostic variables of long-term biochemical outcome after prostate seed brachytherapy.
Ding W; Lee J; Chamberlain D; Cunningham J; Yang L; Tay J
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):962-7. PubMed ID: 22494584
[TBL] [Abstract][Full Text] [Related]
13. American Brachytherapy Society recommends no change for prostate permanent implant dose prescriptions using iodine-125 or palladium-103.
Rivard MJ; Butler WM; Devlin PM; Hayes JK; Hearn RA; Lief EP; Meigooni AS; Merrick GS; Williamson JF
Brachytherapy; 2007; 6(1):34-7. PubMed ID: 17284383
[TBL] [Abstract][Full Text] [Related]
14. Is there a role for postimplant dosimetry after real-time dynamic permanent prostate brachytherapy?
Potters L; Calugaru E; Jassal A; Presser J
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1014-9. PubMed ID: 16682144
[TBL] [Abstract][Full Text] [Related]
15. Variability of prostate brachytherapy pre-implant dosimetry: a multi-institutional analysis.
Merrick GS; Butler WM; Wallner KE; Blasko JC; Michalski J; Aronowitz J; Grimm P; Moran BJ; McLaughlin PW; Usher J; Lief JH; Allen ZA
Brachytherapy; 2005; 4(4):241-51. PubMed ID: 16344253
[TBL] [Abstract][Full Text] [Related]
16. Effect of prostate size and isotope selection on dosimetric quality following permanent seed implantation.
Merrick GS; Butler WM; Dorsey AT; Lief JH
Tech Urol; 2001 Sep; 7(3):233-40. PubMed ID: 11575521
[TBL] [Abstract][Full Text] [Related]
17. Long-term prostate cancer control using palladium-103 brachytherapy and external beam radiotherapy in patients with a high likelihood of extracapsular cancer extension.
Dattoli M; Wallner K; True L; Cash J; Sorace R
Urology; 2007 Feb; 69(2):334-7. PubMed ID: 17320673
[TBL] [Abstract][Full Text] [Related]
18. Transrectal ultrasound-guided interstitial radiation therapy for localized prostate cancer.
Brosman SA; Tokita K
Urology; 1991 Oct; 38(4):372-6. PubMed ID: 1721754
[TBL] [Abstract][Full Text] [Related]
19. Isotope choice and the effect of edema on prostate brachytherapy dosimetry.
Butler WM; Merrick GS; Dorsey AT; Lief JH
Med Phys; 2000 May; 27(5):1067-75. PubMed ID: 10841411
[TBL] [Abstract][Full Text] [Related]
20. Isotope selection for permanent prostate implants? An evaluation of 103Pd versus 125I based on radiobiological effectiveness and dosimetry.
Dicker AP; Lin CC; Leeper DB; Waterman FM
Semin Urol Oncol; 2000 May; 18(2):152-9. PubMed ID: 10875458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
